Plasma and tumor levels of Linc-pint are diagnostic and prognostic biomarkers for pancreatic cancer
Metrics: PDF 2550 views | HTML 2993 views | ?
Le Li1, Guang-Quan Zhang1, Hua Chen1, Zhong-Jie Zhao1, Hong-Ze Chen1, Huan Liu1, Gang Wang1, Yue-Hui Jia2, Shang-Ha Pan1, Rui Kong1, Yong-Wei Wang1, Bei Sun1
1Department of Pancreatic and Biliary Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China
2Department of Epidemiology and Biostatistics, School of Public Health, Qiqihar Medical University, Qiqihar, Heilongjiang, China
Bei Sun, email: [email protected]
Keywords: pancreatic cancer, prognosis, biomarker, Linc-pint, CA19-9
Received: June 06, 2016 Accepted: September 25, 2016 Published: September 30, 2016
Long intergenic non-protein coding RNA, p53 induced transcript (Linc-pint) is a long noncoding RNA (lncRNA) that regulates tumor cell viability and proliferation. We used qRT-PCR and RNA FISH analysis to evaluate Linc-pint levels in the plasma and tumor tissues of pancreatic cancer (PCa) patients. Our data demonstrate that Linc-pint expression is lower in plasma samples from PCa patients than from healthy individuals, and indicate that plasma Linc-pint levels are more sensitive than CA19-9 for detecting PCa. Our data also show that Linc-pint levels are lower in PCa tumors than in adjacent tissues, carcinoma of the ampulla of Vater (CAV) and cholangiocarcinoma (CCA), and suggest that Linc-pint could be used for distinguishing the cause of malignant obstructive jaundice. Low plasma Linc-pint levels correlate with tumor recurrence, while low tumor Linc-pint levels correlate with poor prognosis for PCa patients after pancreatectomy. These results thus indicate that low plasma Linc-pint expression could serve as a minimally invasive biomarker for early PCa detection, and that low Linc-pint levels in PCa tumors could be used for predicting patient prognosis.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.